ALK inhibitors

systematic review meta-analysis network meta-analysis

Select lung cancer (metastatic) ALK positive patients       ALK inhibitors alectinibbrigatinibceritinibcrizotinib vs chemotherapyvs crizotinib       1st line2nd linecrizotinib failurenonsquamous NSCLC

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	progression or death (progression free survival PFS) (5)death (overall survival) (4) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	progression or death (progression free survival PFS)	death (overall survival)
lung cancer (metastatic)
alectinib
ALUR, 2018    NCT	alectinib	chemotherapy	2L	2nd line crizotinib failure	Exploratory	suggesting
ALEX, 2017      NCT	alectinib	crizotinib	1L	1st line	Risk of bias	conclusive
ceritinib
ASCEND-4, 2017      NCT	ceritinib	chemotherapy	1L	1st line nonsquamous NSCLC	Risk of bias	suggesting
ASCEND 5, 2017      NCT	ceritinib	pemetrexed or docetaxel	2L after crizotinib failure	2nd line crizotinib failure		-
crizotinib
Shaw, 2013      NCT	crizotinib	chemotherapy	2L	2nd line	Risk of bias	suggesting
PROFILE 1014, 2014        NCT	crizotinib	chemotherapy	1L	1st line nonsquamous NSCLC	Risk of bias	suggesting